| Stage | CRH | % of rev | CRI | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $11.4B | 100.00% | $752M | 100.00% | CRH ×15.15 |
| Gross profit | $4.4B | 38.79% | $355M | 47.15% | CRI +8.4pp |
| Operating income | $1.9B | 16.64% | $56M | 7.41% | CRH +9.2pp |
| Pre-tax income | $1.7B | 15.08% | $48M | 6.43% | CRH +8.7pp |
| Net income | $1.2B | 10.39% | $37M | 4.87% | CRH +5.5pp |
| Stage | CRH | CRI | Gap · A − B |
|---|---|---|---|
| Revenue | $11.4B100.00% | $752M100.00% | CRH ×15.15 |
| Gross profit | 38.79%$4.4B | 47.15%$355M | CRI +8.4pp |
| Operating income | 16.64%$1.9B | 7.41%$56M | CRH +9.2pp |
| Pre-tax income | 15.08%$1.7B | 6.43%$48M | CRH +8.7pp |
| Net income |
| 10.39%$1.2B |
| 4.87%$37M |
| CRH +5.5pp |
None
No disclosed counterparties: CRH.